Positron emission tomography in gastric and asophageal cancer

Current Opinion in Oncology

Volumn 16, Issue 4, 2004, Pages 359-363

  Flamen, Patrick ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Gastroesophageal cancer; Positron emission tomography; Staging; Therapy response assessment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; ESOPHAGUS CANCER; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; MEDICAL ASSESSMENT; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURVIVAL RATE; TECHNIQUE;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REMISSION INDUCTION; STOMACH NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 3042842662     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000128276.13585.fa     Document Type: Review

References (22)

1. Stahl A, Ott K, Weber WA, et al.: FDG-PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003, 30:288-295. First full paper reporting a difference in FDG accumulation in squamous cell cancer compared with adenocarcinoma. One on four adenocarcinomata of the gastroesophageal junction does not accumulate FDG.
2. Van Riet J, Alaerts H, Ectors N, et al.: FDG avidity in adenocarcinoma of the gastro-oesophageal junction in relation to histopathological findings. Eur J Nucl Med Mol Imaging 2003, 30:3218.
3. Kawamura T, Kusakabe T, Sugino T, et al.: Expression of glucose transporter-1 in human gastric carcinoma: association with tumour aggressiveness, metastasis, and patient survival. Cancer 2001, 92:634-641.
4. Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-deoxy-d-glucose positron emission tomography for gastric cancer. World J Surg 2004, 17:28:274-253. This report indicates that gastric adenocarcinoma does not accumulate FDG in 25[ref] of patients. In tumors that do take up the tracer, the uptake intensity is related to patient prognosis.
5. Flamen P, Lerut A, Van Cutsem E, et al.: Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000, 18:3202-3210.
6. Rice TW, Zuccaro G Jr, Adelstein DJ, et al.: Esophageal carcinoma: depth of tumour invasion is predictive of regional lymph node status. Ann Thorac Surg 1998, 65:787-792.
7. Choi JY, Lee KH, Shim YM, et al.: Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000, 41:808-815.
8. Lerut T, Flamen P, Ectors N, et al.: Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000, 232:743-751.
9. Yoon YC, Lee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 2003, 227:764-770
10. Schöder H, Larson S, Yeung H: PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004, 45:725-813. This review on the use of PET-CT technology deals with the specific advantages of using image fusion in diagnosis and follow-up of gastroesophageal carcinoma.
11. Wallace MB, Nietert PJ: Earle C, et al.: An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/ laparoscopy. Ann Thorac Surg 2002, 74:1026-1032.
12. Flamen P, Lerut A, Van Cutsem E, et al.: The utility of positron emission tomography (PET) for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000, 120:1085-1092.
13. 18F-fluoro-deoxy-D-glucose (FDG) for diagnosis of recurrent gastric cancer. Eur J Nucl Med 2002, 29:525-529.(6) This report is the only one to have studied the value of FDG-PET for the diagnosis of recurrent gastric cancer. A major problem was the lack of FDG avidity found in some of the recurrences, resulting in a high rate of false negative reports.
14. Alavi A, Kung JW, Zhuang H: Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med 2004, 34:56-69.
15. Spaepen K, Stroobants S, Dupont P, et al.: FDG-PET monitoring of tumour response to chemotherapy: does FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003, 30:682-688. The authors studied, in a severe combined immunodeficiency disease mouse model of lymphoma, the kinetics of cell kill, apoptosis, and inflammation after intraperitoneal chemotherapy. The authors used microautoradiography and immunohistochemistry. The conclusion was that the timing of posttreatment PET is crucial because of the inflammatory response in the tumor, which can artefactually compensate for the loss of FDG accumulation after an effective treatment.
16. Weber WA, Ott K, Becker K, et al.: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058-3065.
17. Ott K, Fink U, Becker K, et al.: Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003, 21:4604-4610. The Munich University reports on the accurate prediction of the histopathologic response by means of serial FDG-PET performed before and on day 14 of cisplatinum-based polychemotherapy. The early metabolic responses as measured by PET are related to overall and disease-free survival. This article provides a basis for using serial FDG-PET as a surrogate response marker.
18. Laking GR, Price PM: FDG-PET for response assessment: answers in search of questions. Ann Oncol 2002, 13:345-347.
19. Brücher B, Weber W, Bauer M, et al.: Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001, 233:300-309.
20. Flamen P, Van Cutsem E, Lerut A, et al.: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13:361-368.
21. Arslan N, Miller T, Dehdashti F, et al.: Evaluation of response to neoadjuvant therapy by quantitative FDG-PET in patients with esophageal cancer. Molecular Imaging Biol 2002, 4:301-310.
22. Downey RJ, Akhurst T, Ilson D, et al.: Whole body FDG PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003, 21:428-432.